Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COG-201
- Development stage
- Preclinical
- Lead developer
- Cognigenics
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intranasal
01
Overview
COG-201 is an investigational gene therapy candidate being developed by Cognigenics for the treatment of Mild Cognitive Impairment (MCI) associated with anxiety. The therapeutic utilizes an adeno-associated virus (AAV) vector to deliver short hairpin RNA (shRNA) via an intranasal route, facilitating non-invasive delivery to the central nervous system. COG-201 is designed to selectively knock down the expression of specific genetic targets identified through Cognigenics' G-NAi (Gene-Network Artificial Intelligence) platform, which focuses on modulating neural networks to improve cognitive function and alleviate comorbid emotional symptoms. By targeting specific serotonin receptor networks or related pathways in the brain, the therapy aims to provide a long-lasting modulation of neural circuits involved in memory and anxiety regulation. It is currently in the preclinical stage of development.
- Other names
- COG-201COG201COG 201
02
Targets
5-hydroxytryptamine receptor 2AHTR2A (Serotonin receptor 5-HT2A)
Beyond the preview
Go deeper on COG-201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COG-201.